Cited by 3,011Hepatitis C virus researchLiver Disease Diagnosis and TreatmentLiver physiology and pathology

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Poynard, Thierry, Bedossa, Pierre, Opolon, Pierre·1997·The Lancet

Open this paper in CoChat — free account

Abstract

Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hépatite C (OBSVIRC) population, the Cohorte Hépatite C Pitié-Salpétrière (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, F0 = no fibrosis, F4 = cirrhosis, and histological activity on a four-point scale, A0 = no activity, A3 = severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained. We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit = one stage, 4 units = cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)07642-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Self-citation
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M. A., Hoofnagle, J. H., Manns, M. P., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,591
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,212
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,191
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
Poynard, T., Leroy, V., Cohard, M., Thévenot, T., Mathurin, P., Opolon, P., & Zarski, J. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Self-citation
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., INOUE, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 597
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
Bisceglie, A. M. D., Goodman, Z. D., Ishak, K. G., Hoofnagle, J. H., Melpolder, J. J., & Alter, H. J. (1991) · Hepatology · doi:10.1002/hep.1840140603 · Cited by 538
Epidemiology of Hepatitis C in the West
Alter, M. J. (1995) · Seminars in Liver Disease · doi:10.1055/s-2007-1007259 · Cited by 482
A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
Poynard, T., Bédossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., TREPO, C. G., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 454
Self-citation

Show all 24 references

Research works printed but not linked: 1

1995, Bilan initial. Association Francoise pour ľEtude du Foie, Lyon 1994, Gastroenterol Clin Biol, 19, 81

Sorted by citations

Items 801–900 of 1,001

A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis
Xi, Y., LaCanna, R., N’Diaye, E.-N., Gierke, S., Ma, H., Caplazi, P., Sagolla, M. S., Huang, Z., Lucio, L., Arlantico, A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.009 · Cited by 51
Factors associated with injection cessation, relapse and initiation in a community‐based cohort of injection drug users in Chennai, India
Mehta, S. H., Sudarshi, D., Srikrishnan, A. K., Celentano, D. D., Vasudevan, C. K., Anand, S., Kumar, M. S., Latkin, C. A., Solomon, S., & Solomon, S. S. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03602.x · Cited by 49
Ribavirin monotherapy for chronic hepatitis C
Brok, J. S., Gluud, L. L., & Gluud, C. N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005527.pub2 · Cited by 49
Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population‐based prospective cohort of Japanese men and women
Kurahashi, N., Inoue, M., Iwasaki, M., Tanaka, Y., Mizokami, M., Tsugane, S., & for the JPHC Study Group (2008) · International Journal of Cancer · doi:10.1002/ijc.24121 · Cited by 49
The impact of hepatic steatosis on the natural history of chronic hepatitis C infection
Cross, T. J. S., Quaglia, A., Hughes, S., Joshi, D., & Harrison, P. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01098.x · Cited by 49
Increased Mortality Among Persons Infected With Hepatitis C Virus
Omland, L. H., Jepsen, P., Krarup, H. B., Schønning, K., Lind, B., Kromann‐Andersen, H., Homburg, K. M., Christensen, P. B., Sørensen, H. T., & Obel, N. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.014 · Cited by 49
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Ramos, C. A., Saliba, R. M., Padua, L. D., Khorshid, O., Shpall, E. J., Giralt, S. A., Patah, P., Hosing, C. M., Popat, U., Rondon, G., et al. (2009) · Haematologica · doi:10.3324/haematol.13756 · Cited by 49
Comparative Risk of Liver-Related Mortality From Chronic Hepatitis B Versus Chronic Hepatitis C Virus Infection
Falade-Nwulia, O. O., Seaberg, E. C., Rinaldo, C. R., Badri, S. M., Witt, M. D., & Thio, C. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis432 · Cited by 49
Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease
Anand, B. S. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i16.2409 · Cited by 49
The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C
Myers, R., Patel, K., Pianko, S., Poynard, T., & McHutchison, J. G. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00387.x · Cited by 49
Self-citation
Hepatitis C Virus Dynamics during Natural Infection Are Associated with Long‐Term Histological Outcome of Chronic Hepatitis C Disease
Sullivan, D. G., Bruden, D. J. T., Deubner, H., McArdle, S., Chung, M., Christensen, C., Hennessy, T., Homan, C., Williams, J. L., McMahon, B. J., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/518895 · Cited by 49
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease.
Vecchiet, J., Falasca, K., Cacciatore, P., Zingariello, P., Dalessandro, M., Marinopiccoli, M., D'Amico, E., Palazzi, C., Petrarca, C., Conti, P., et al. (2005) · PubMed · Cited by 49
Nuclear factor-κB in the liver of patients with chronic hepatitis C: Decreased RelA expression is associated with enhanced fibrosis progression
Boya, P., Larrea, E., Sola, I., Majano, P. L., Jiménez, C., Civeira, M.-P., & Prìeto, J. (2001) · Hepatology · doi:10.1053/jhep.2001.29002 · Cited by 49
Natural History of Hepatitis B and C Virus Infections
Iino, S. (2002) · Oncology · doi:10.1159/000048271 · Cited by 49
Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice
Lee, P. A., Blatt, L. M., Blanchard, K. S., Bouhana, K., Pavco, P. A., Bellon, L., & Sandberg, J. A. (2000) · Hepatology · doi:10.1053/jhep.2000.16599 · Cited by 49
Hepatitis C virus infection in systemic lupus erythematosus: a case-control study.
Perlemuter, G., Cacoub, P., Sbaï, A., Hausfater, P., Thibault, V., Du-Boutin, L. T. H., Wechsler, B., Buffet, C., & Piette, J. C. (2003) · PubMed · Cited by 49
Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens
Hunt, J., Gordon, F. D., Lewis, D. W., Pomfret, E. A., Pomposelli, J. J., Jenkins, R. L., & Khettry, U. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.27803 · Cited by 49
A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma
Stroffolini, T., & Stroffolini, G. (2023) · Cancers · doi:10.3390/cancers15082388 · Cited by 50
Alcohol use among patients with HIV infection
Bonacini, M. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31519-4 · Cited by 48
Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
Deuffic‐Burban, S., Deltenre, P., Louvet, A., Canva, V., Dharancy, S., Hollebecque, A., Boitard, J., Henrion, J., Yazdanpanah, Y., & Mathurin, P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.04.012 · Cited by 48
Increased Susceptibility to Liver Fibrosis with Age Is Correlated with an Altered Inflammatory Response
Mahrouf‐Yorgov, M., de l’Hortet, A. C., Cosson, C., Slama, A., Abdoun, E., Guidotti, J., Fromenty, B., Mitchell, C., & Gilgenkrantz, H. (2011) · Rejuvenation Research · doi:10.1089/rej.2010.1146 · Cited by 48
A common polymorphism in theABCB11gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease
Iwata, R., Baur, K., Stieger, B., Mertens, J. C., Daly, A. K., Frei, P., Braun, J., Vergopoulos, A., Stickel, F., Sabrane, K., et al. (2010) · Clinical Science · doi:10.1042/cs20100246 · Cited by 48
Performance of liver stiffness measurements by transient elastography in chronic hepatitis
Ferraioli, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i1.49 · Cited by 48
Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990
Krahn, M. D., Wong, J. B., Heathcote, J., Scully, L. J., & Seeff, L. B. (2004) · Medical Decision Making · doi:10.1177/0272989x03261568 · Cited by 49
Habitual Betel Quid Chewing as a Risk Factor for Cirrhosis
Tsai, J., Jeng, J., Chuang, L.-Y., Ho, M., Ko, Y.-C., Lin, Z., Hsieh, M., Chen, S.-C., Chuang, W.-L., Wang, L., et al. (2003) · Medicine · doi:10.1097/01.md.0000090401.56130.59 · Cited by 48
Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity
Zeuzem, S., Alberti, A., Rosenberg, W. M., Marcellin, P., Moisés Diago, M., Negro, F., Prati, D., Puoti, C., Roberts, S., & Shiffman, M. L. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03073.x · Cited by 48
HEPATITIS C VIRUS AND LIVER TRANSPLANTATION
Ahmed, A., & Keeffe, E. B. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70210-5 · Cited by 48
Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?
Arends, J. E., Lieveld, F. I., Boeijen, L. L., de Kanter, C. T. M. M., van Erpecum, K. J., Salmon, D., Hoepelman, A. I. M., Asselah, T., & Ustianowski, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.034 · Cited by 49
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy
Oze, T., Hiramatsu, N., Yakushijin, T., Mochizuki, K., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Fukui, H., Inui, Y., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.043 · Cited by 47
Hyaluronic acid–tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis
Yang, J., Kong, W. H., Sung, D. K., Kim, H., Kim, T. H., Lee, K. C., & Hahn, S. K. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.10.002 · Cited by 47
The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers
Davis, G. L., & Roberts, W. L. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0087-2 · Cited by 47
Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection
Lauletta, G., Russi, S., Conteduca, V., Sansonno, L., Dammacco, F., & Sansonno, D. E. (2013) · Medicine · doi:10.1097/md.0b013e31829d2abc · Cited by 47
Improving the accuracy of long‐term prognostic estimates in hepatitis C virus infection
Yi, Q., Wang, P., & Krahn, M. D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00484.x · Cited by 47
Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1
Huang, C., Yeh, M., Huang, J., Yang, J., Hsieh, M., Lin, Z., Chen, S., Wang, L., Hsi, E., Juo, S. H., et al. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.12.002 · Cited by 47
Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection
McMahon, B. J., Bruden, D. J. T., Bruce, M. G., Livingston, S., Christensen, C., Homan, C., Hennessy, T. W., Williams, J. L., Sullivan, D., Rosen, H. R., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.056 · Cited by 47
Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems
Tsui, J. I., Pletcher, M. J., Vittinghoff, E., Seal, K. H., & Gonzales, R. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.027 · Cited by 47
Cost‐effectiveness of rapid hepatitis C virus ( HCV ) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs
Schackman, B. R., Leff, J. A., Barter, D. M., DiLorenzo, M. A., Feaster, D. J., Metsch, L. R., Freedberg, K. A., & Linas, B. P. (2014) · Addiction · doi:10.1111/add.12754 · Cited by 48
Estimating chronic hepatitis C prognosis using transient elastography‐based liver stiffness: A systematic review and meta‐analysis
Erman, A., Sathya, A., Nam, A., BIELECKI, J. M., Feld, J. J., Thein, H., Wong, W. W. L., Grootendorst, P. V., & Krahn, M. D. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12846 · Cited by 47
Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage
Serra, M. Á., Rodríguez, F. G., del Olmo, J. A., Escudero, A., & Rodrigo, J. M. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00372.x · Cited by 47
Chronic hepatitis C with normal aminotransferase levels
Ahmed, A., & Keeffe, E. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.073 · Cited by 47
Hepatitis C is more severe in drug users with human immunodeficiency virus infection
Romeo, Rumi, Donato, Cargnel, Viganò, Mondelli, M. U., Cesana, & Colombo (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00230.x · Cited by 47
Characterization of in vitro healthy and pathological human liver tissue periodicity using backscattered ultrasound signals
Machado, C. B., Pereira, W. C. D. A., Meziri, M., & Laugier, P. (2006) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2006.01.009 · Cited by 45
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C
Prati, D., Shiffman, M. L., Moisés Diago, M., Gane, E. J., Reddy, K. R., Pockros, P. J., Farci, P., O’Brien, C., Lardelli, P., Blotner, S. D., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.004 · Cited by 47
Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s
Ferenci, P., Ferenci, S., Datz, C., Rezman, I., Oberaigner, W., & Strauß, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.023 · Cited by 47
Suppressive effects of 17β-estradiol on hepatic fibrosis in CCl4-induced rat model
Liu, Q.-H., Li, D., Huang, X., Zong, C.-H., Xu, Q., & Lu, H.-M. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i9.1315 · Cited by 50
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression
Somsouk, M., Lauer, G. M., Casson, D. R., Terella, A. M., Day, C. L., Walker, B. D., & Chung, R. T. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00391-3 · Cited by 47
Combination Therapy with Interferon-?? and Ribavirin for Hepatitis C
Collier, J. D., & Chapman, R. W. (2001) · BioDrugs · doi:10.2165/00063030-200115040-00003 · Cited by 46
Outcomes of a Hepatitis C Screening Program at a Large Urban VA Medical Center
Groom, H. C., Dieperink, E. W., Nelson, D. B., Garrard, J. M., Johnson, J. R., Ewing, S. L., Stockley, H., Durfee, J. M., Jonk, Y. C., Willenbring, M. L., et al. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31802dc56f · Cited by 46
Management of chronic hepatitis C
Re, V. L., & Kostman, J. R. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.025403 · Cited by 46
The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression
John‐Baptiste, A., Krahn, M. D., Heathcote, J., Laporte, A., & TOMLINSON, G. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.015 · Cited by 46
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection
Trembling, P. M., Lampertico, P., Parkes, J., Tanwar, S., Viganò, M., Facchetti, F., Colombo, M., & Rosenberg, W. M. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12161 · Cited by 46
Severe alcoholic relapse after liver transplantation: What consequences on the graft? A study based on liver biopsies analysis
Erard‐Poinsot, D., Guillaud, O., Hervieu, V., Thimonier, E., Vallin, M., Chambon‐Augoyard, C., Boillot, O., Scoazec, J., & Dumortier, J. (2016) · Liver Transplantation · doi:10.1002/lt.24425 · Cited by 46
S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“
Zimmermann, T., Jansen, P., Sarrazin, C., Vollmar, J., & Zeuzem, S. (2018) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0598-5242 · Cited by 43
Different Hepatitis C Virus (HCV) RNA Load Profiles Following Seroconversion among Injecting Drug Users without Correlation with HCV Genotype and Serum Alanine Aminotransferase Levels
Beld, M., Penning, M. T., McMorrow, M., Gorgels, J. P. M. C., van den Hoek, A., & Goudsmit, J. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.872-877.1998 · Cited by 46
Epidemiology and Natural History of Hepatitis C Virus Infection in Injection Drug Users: Implications for Treatment
Sulkowski, M., & Thomas, D. L. (2005) · Clinical Infectious Diseases · doi:10.1086/427440 · Cited by 46
The Veterans Aging Cohort Study: Observational Studies of Alcohol Use, Abuse, and Outcomes Among Human Immunodeficiency Virus–Infected Veterans
Conigliaro, J. C., Madenwald, T., BRYANT, K. J., Braithwaite, R. S., Gordon, A. J., Fultz, S. L., Maisto, S. A., Samet, J. H., Kraemer, K. L., Cook, R. L., et al. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000113414.73220.21 · Cited by 46
Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation
Shepherd, J., Brodin, H. F. T., Cave, C. B., Waugh, N. R., Price, A., & Gabbay, J. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050063 · Cited by 46
Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference
Ahmed, A., & Keeffe, E. B. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01875.x · Cited by 46
Hepatitis C virus genotypes: epidemiological and clinical associations
Kleter, B., Brouwer, J. T., Nevens, F., van Doorn, L., Elewaut, A., Versieck, J., Michielsen, P. P., Hautekèete, M., Chamuleau, R. A. F. M., Brenard, R., et al. (1998) · Liver International · doi:10.1111/j.1600-0676.1998.tb00124.x · Cited by 46
Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial
Dieperink, E., Fuller, B., Isenhart, C., McMaken, K., Lenox, R., Pocha, C., Thuras, P., & Hauser, P. (2014) · Addiction · doi:10.1111/add.12679 · Cited by 45
Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression
Kim, S. U., Park, J. Y., Kim, D. Y., Ahn, S. H., Choi, E. H., Seok, J. Y., Lee, J. M., Park, Y. N., Chon, C. Y., & Han, K. (2010) · Hepatology International · doi:10.1007/s12072-010-9201-7 · Cited by 45
Noninvasive assessment of liver function
Helmke, S. M., Colmenero, J., & Everson, G. T. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000167 · Cited by 45
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
van der Meer, A. J., Wedemeyer, H. H., Feld, J. J., Hansen, B. E., Manns, M. P., Zeuzem, S., & Janssen, H. L. A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.043 · Cited by 45
Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver
Deng, Y., Palmeri, M. L., Rouze, N. C., Rosenzweig, S. J., Abdelmalek, M. F., & Nightingale, K. R. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.02.019 · Cited by 45
Role of assessing liver fibrosis in management of chronic hepatitis C virus infection
Carmona, I., Cordero, P., Ampuero, J., Rojas, Á., & Romero‐Gómez, M. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.017 · Cited by 45
EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
Poynard, T., Moussalli, J., Ratziu, V., Regimbeau, C., & Opolon, P. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70244-0 · Cited by 45
Self-citation
Simulation of hepatitis C based on a mandatory reporting system
Sagmeister, M., Renner, E. L., Müllhaupt, B., & Wong, J. B. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200201000-00006 · Cited by 44
Clinical management of HCV carriers with normal aminotransferase levels
Puoti, C., Guido, M., Mangia, A., Persico, M., & Prati, D. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00185-3 · Cited by 45
Chronic Hepatitis C Virus Infection: Does It Really Impact Health–Related Quality of Life? A Study in Rural Egypt
Schwarzinger, M., Dewedar, S. A., Rekacewicz, C., Elaziz, K. M. A., Fontanet, A. L., Carrat, F., & Mohamed, M. K. (2004) · Hepatology · doi:10.1002/hep.20468 · Cited by 46
Association of inflammatory and anti‐inflammatory cytokines with insulin resistance in chronic hepatitis C
Hung, C., Lee, C., Chen, C., Hu, T., Jiang, S., Wang, J., Lu, S., & Wang, P. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.01991.x · Cited by 45
Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe
Fattovich, G., Ribero, M. L., Pantalena, M., Diodati, G., Almasio, P. L., Nevens, F., Tremolada, F., Degos, F., Rai, J., Solinas, A., et al. (2001) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2001.00291.x · Cited by 45
Cost‐effectiveness of sofosbuvir in the treatment of patients with hepatitis C
Leleu, H., Blachier, M., & Rosa, I. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12311 · Cited by 44
Effects of alcohol consumption on viral hepatitis B and C
Xu, H., Wang, C., Zhou, Q., & Gao, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i33.10052 · Cited by 44
Similar Progression of Fibrosis Between HIV/HCV–Infected and HCV–Infected Patients: Analysis of Paired Liver Biopsy Samples
Sterling, R. K., Wegelin, J. A., Smith, P. G., Stravitz, R. T., Luketic, V. A., Fuchs, M. A., Puri, P., Shiffman, M. L., Contos, M. J., Mills, A. S., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.08.004 · Cited by 44
Factors Influencing the Progression of Fibrosis in Patients with Recurrent Hepatitis C After Liver Transplantation Under Antiviral Therapy
Walter, T., Dumortier, J., Guillaud, O., Hervieu, V., Scoazec, J., & Boillot, O. (2007) · Liver Transplantation · doi:10.1002/lt.21000 · Cited by 44
Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?
Karsdal, M. A., Detlefsen, S., Daniels, S. J., Nielsen, M. J., Krag, A. A., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30969 · Cited by 44
Prevalence of Hepatitis C–Related Cirrhosis in Elderly Asian Patients Infected in Childhood
D'Souza, R., Glynn, M. J., Ushiro‐Lumb, I., Feakins, R. M., Domizio, P., Mears, L., ALSCED, E., KUMAR, P., Sabin, C. A., & Foster, G. R. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00527-6 · Cited by 43
A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection
Reynolds, W. F., Patel, K., Pianko, S., Blatt, L. M., Nicholas, J. J., & McHutchison, J. G. (2002) · Genes and Immunity · doi:10.1038/sj.gene.6363880 · Cited by 44
Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign
D'Souza, R., Glynn, M. J., Alstead, E. M., Osonayo, C., & Foster, G. R. (2004) · QJM · doi:10.1093/qjmed/hch060 · Cited by 44
Effect of Hepatitis C Virus Infection and Abstinence From Alcohol on Survival in Patients With Alcoholic Cirrhosis
Serra, M. Á., Escudero, A., Rodrı́guez, F., del Olmo, J. A., & Rodrigo, J. M. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200302000-00016 · Cited by 44
Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
Rumi, M. G., Filippi, F. D., Donato, M. F., Ninno, E. D., & Colombo, M. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00328.x · Cited by 44
Acetaldehyde accelerates HCV-induced impairment of innate immunity by suppressing methylation reactions in liver cells
Ganesan, M., Zhang, J., Bronich, T. K., Poluektova, L. Y., Donohue, T. M., Tuma, D. J., Kharbanda, K. K., & Osna, N. A. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00183.2015 · Cited by 43
Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection
Huang, C., Dai, C., Yeh, M., Huang, C., Tai, C., Hsieh, M., Liang, P., Lin, Y., Hsieh, M., Yang, H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.011 · Cited by 43
Impact of alcohol on hepatitis C virus replication and interferon signaling
McCartney, E. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i11.1337 · Cited by 43
Prevention of hepatocellular carcinoma complicating chronic hepatitis C
Ueno, Y., Sollano, J. D., & Farrell, G. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05814.x · Cited by 43
Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients
Patel, S., Jinjuvadia, R., Patel, R. A., & Liangpunsakul, S. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000400 · Cited by 43
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma
Rasi, G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i37.4986 · Cited by 43
Natural history of chronic hepatitis C
Yatsuhashi, H., & Yano, M. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02122.x · Cited by 43
Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus
Hung, C., Lee, C. ‐., Wang, J., Tung, H., CHEN, C., & Lu, S. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03925.x · Cited by 43
Hepatitis C and HIV Infections: Implications for Clinical Care in Injection Drug Users
Sullivan, L. E., & Fiellin, D. A. (2004) · American Journal on Addictions · doi:10.1080/10550490490265271 · Cited by 43
Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C
Shiha, G. E.-S., & Zalat, K. (2011) · InTech eBooks · doi:10.5772/20110 · Cited by 42
Disease progression and the risk factor analysis for chronic hepatitis C
Sinn, D. H., Paik, S. W., Kang, P., Kil, J. S., Park, S. U., Lee, S., Song, S. M., Gwak, G., Choi, M. S., Lee, J. H., et al. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01860.x · Cited by 42
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis
Isgrò, G., Calvaruso, V., Andreana, L., Luong, T. V., Garcovich, M., Manousou, P., Alibrandi, A., Maimone, S., Marelli, L., Davies, N., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0694-9 · Cited by 42
Significant Reductions in Drinking Following Brief Alcohol Treatment Provided in a Hepatitis C Clinic
Dieperink, E. W., Ho, S. B., Heit, S., Durfee, J. M., THURAS, P. D., & Willenbring, M. L. (2010) · Psychosomatics · doi:10.1176/appi.psy.51.2.149 · Cited by 42
Mast cells and the liver aging process
Grizzi, F., Caro, G. D., Laghi, L., Hermonat, P. L., Mazzola, P., Nguyen, D. D. T., Radhi, S., Figueroa, J. A., Cobos, E., Annoni, G., et al. (2013) · Immunity & Ageing · doi:10.1186/1742-4933-10-9 · Cited by 41
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection
Hui, C., Lau, E., Wu, H. Y., Monto, A., Kim, M. H., Luk, J. M., Lau, G. K. K., & Wright, T. L. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.07.003 · Cited by 42
Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients
Bouzgarrou, N., Fodha, I., Othman, S. B., Achour, A., Grattard, F., Trabelsi, A., & Pozzetto, B. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20485 · Cited by 42
Idoxifene and Estradiol Enhance Antiapoptotic Activity Through Estrogen Receptor-β in Cultured Rat Hepatocytes
Inoue, H., Shimizu, I., Lu, G., Itonaga, M., Cui, X., Okamura, Y., Shono, M., Honda, H., Inoue, S., Muramatsu, M., et al. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022553119715 · Cited by 43
Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus
Tural, C., Tor, J., Sanvisens, A., Pérez‐Álvarez, N., Martínez-Carbonell, E., Ojanguren, I., García‐Samaniego, J., Rockstroh, J. K., Barluenga, E., Muga, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.019 · Cited by 42
CD56+dim and CD56+bright cell activation and apoptosis in hepatitis C virus infection
Lin, A., Gonzalez, S. A., Cunningham-Rundles, S., Dorante, G., MARSHALL, S., TIGNOR, A., HA, C., Jacobson, I. M., & Talal, A. H. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02523.x · Cited by 42

Authors: Poynard, T., Bedossa, P., & Opolon, P.
Affiliations: Centre National de la Recherche Scientifique (FR)
Corresponding author: Poynard, Thierry
ORCID: Poynard, Thierry
Venue: The Lancet
Publisher: Elsevier BV
Published: 1997-03
Volume: 349
Issue: 9055
Pages: 825-832
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(96)07642-8
OpenAlex: W2132290252
Cited by: 3,011
References: 24
Citations by year: 2026: 16 · 2025: 35 · 2024: 33 · 2023: 38 · 2022: 43 · 2021: 45 · 2020: 71 · 2019: 74 · 2018: 72 · 2017: 90 · 2016: 117 · 2015: 141 · 2014: 120 · 2013: 138 · 2012: 114
FWCI: 60.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Assistance Publique - Hôpitaux de Paris
Assistance publique-Hôpitaux de Paris
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: chronic hepatitis C, liver fibrosis progression, natural history (disease), METAVIR scoring, liver cirrhosis, age at infection, alcohol consumption, sex differences, HCV genotypes, HCV viraemia, host factors, infection duration, histological activity, liver biopsy
MeSH terms: Adult, Age Factors, Alcohol Drinking, Biopsy, Cross-Sectional Studies, Female, Hepatitis, Chronic, Hepatitis C, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, Sex Factors, Time Factors, Prevalence, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks